EUVIMEDEUVIMED entdecken
Crossref

Ischemic stroke risk in patients with dopamine agonist‐treated hyperprolactinemia

Amit Akirov iD, Yaron Rudman iD, Yael Sharon, Ilan Shimon iD, Shiri Kushnir iD, Talia Diker-Cohen iD

Journal of Neuroendocrinology · 2025

DOI: 10.1111/jne.13494 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuroendocrinology, 2025. Verfasst von Amit Akirov und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Hyperprolactinemia, Dopamine Agonists, Ischemic Stroke. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Data on the risk of stroke in patients with hyperprolactinemia are limited. This study aimed to evaluate the association between hyperprolactinemia and ischemic stroke in a large cohort and identify predictors of stroke in this population. This was a retrospective cohort study comparing the incidence of ischemic stroke in patients with dopamine agonist‐treated hyperprolactinemia to matched controls in a 1:5 ratio. The primary outcome was the diagnosis of ischemic stroke. The cohort included 2440 patients with DA‐treated hyperprolactinemia patients (mean age ± SD: 38.42 ± 14.57 years, 60.2% women) matched to 12,022 controls (mean age ± SD: 38.15 ± 14.36 years, 60.8% women). Ischemic stroke occurred in 195 patients with hyperprolactinemia (8.0%) and 747 controls (6.21%) (adjusted HR 1.24, 95% CI 1.06–1.46). Patients with hyperprolactinemia developed stroke at a younger age (57.75 ± 15.88 years vs. 60.18 ± 15.20 years, p = .05). Patients with PRL levels >5× ULN at diagnosis had a higher stroke incidence than those with lower levels (9.73% vs. 6.85%; HR 1.48, 95% CI 1.11–1.97). Longer time to prolactin normalization was associated with a higher incidence of stroke (median 21.88 vs. 13.78 months; p = .0005). In multivariate analysis, age ≥60 years, male gender, hypertension, type 1 or type 2 diabetes mellitus, and ischemic heart disease were significant predictors of stroke in patients with hyperprolactinemia. Dopamine agonist‐treated hyperprolactinemia is associated with an increased risk of ischemic stroke compared to well‐matched controls from the general population. Higher prolactin levels at diagnosis and a longer time to normalization were linked to a greater risk of stroke.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperprolactinemiaDopamine AgonistsIschemic StrokeHumansFemaleMaleMiddle AgedRetrospective StudiesAdultAgedRisk FactorsIncidenceProlactinCohort Studies

Stichwörter der Autor:innen

Prolactinomadopamine agonisthyperprolactinemiapituitarystroke

Substanzen

Dopamine AgonistsProlactin

Autor:innen und Institutionen

  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Institute of Endocrinology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
  • Ophthalmology Department, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
  • Research Authority, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.

ORCID-Profile: Amit Akirov, Yaron Rudman, Ilan Shimon, Shiri Kushnir, Talia Diker-Cohen

Zitieren

APA

Akirov, A., Rudman, Y., Sharon, Y., Shimon, I., Kushnir, S., & Diker-Cohen, T. (2025). Ischemic stroke risk in patients with dopamine agonist‐treated hyperprolactinemia. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.13494

Vancouver

Akirov A, Rudman Y, Sharon Y, Shimon I, Kushnir S, Diker-Cohen T. Ischemic stroke risk in patients with dopamine agonist‐treated hyperprolactinemia. Journal of Neuroendocrinology. 2025. doi:10.1111/jne.13494

BibTeX
@article{Akirov2025,
  author = {Akirov, Amit and Rudman, Yaron and Sharon, Yael and Shimon, Ilan and Kushnir, Shiri and Diker-Cohen, Talia},
  title = {Ischemic stroke risk in patients with dopamine agonist‐treated hyperprolactinemia},
  journal = {Journal of Neuroendocrinology},
  year = {2025},
  doi = {10.1111/jne.13494}
}
Kostenlos starten →